DE69227400T2 - Impfstoffe und Verfahren zu ihrer Herstellung - Google Patents

Impfstoffe und Verfahren zu ihrer Herstellung

Info

Publication number
DE69227400T2
DE69227400T2 DE69227400T DE69227400T DE69227400T2 DE 69227400 T2 DE69227400 T2 DE 69227400T2 DE 69227400 T DE69227400 T DE 69227400T DE 69227400 T DE69227400 T DE 69227400T DE 69227400 T2 DE69227400 T2 DE 69227400T2
Authority
DE
Germany
Prior art keywords
virus
vaccine
inactivation
propiolactone
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69227400T
Other languages
German (de)
English (en)
Other versions
DE69227400D1 (de
Inventor
John Sidney Woodside Park London N12 7Dy Oxford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Sierovaccinogeno Italiano Isi SpA
Original Assignee
Hvivo Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hvivo Services Ltd filed Critical Hvivo Services Ltd
Publication of DE69227400D1 publication Critical patent/DE69227400D1/de
Application granted granted Critical
Publication of DE69227400T2 publication Critical patent/DE69227400T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Telephone Function (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69227400T 1991-05-17 1992-05-15 Impfstoffe und Verfahren zu ihrer Herstellung Expired - Fee Related DE69227400T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110808A GB9110808D0 (en) 1991-05-17 1991-05-17 Aids vaccine and method for its production

Publications (2)

Publication Number Publication Date
DE69227400D1 DE69227400D1 (de) 1998-12-03
DE69227400T2 true DE69227400T2 (de) 1999-07-01

Family

ID=10695252

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227400T Expired - Fee Related DE69227400T2 (de) 1991-05-17 1992-05-15 Impfstoffe und Verfahren zu ihrer Herstellung

Country Status (16)

Country Link
US (1) US5698432A (enExample)
EP (1) EP0514199B1 (enExample)
JP (1) JPH05328967A (enExample)
KR (1) KR0149182B1 (enExample)
AT (1) ATE172642T1 (enExample)
AU (1) AU652447B2 (enExample)
BR (1) BR9201848A (enExample)
CA (1) CA2068817A1 (enExample)
DE (1) DE69227400T2 (enExample)
ES (1) ES2127203T3 (enExample)
GB (1) GB9110808D0 (enExample)
IE (1) IE921556A1 (enExample)
IN (1) IN174080B (enExample)
NZ (1) NZ242780A (enExample)
SG (1) SG49763A1 (enExample)
ZA (1) ZA923607B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131427T2 (de) * 1991-05-28 1999-11-25 Kabushiki Kaisha Toshiba, Kawasaki Arbeitsvorrichtung
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
DE19520216C2 (de) * 1995-06-01 1997-04-10 Frey Rainer H Vakzine zur Prophylaxe und Therapie von AIDS, und Verfahren zur Herstellung
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
DE19916085A1 (de) * 1998-10-28 2000-05-04 Sonntag Hans Guenther Verfahren zur Herstellung eines antiviralen Mittels
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
WO2001046390A2 (en) * 1999-12-20 2001-06-28 Agricultural Research Council Method of inactivating microorganisms
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
AU2002322284A1 (en) 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
AU2002258268A1 (en) * 2001-12-07 2003-06-17 Genexine Co., Ltd. Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US8497112B2 (en) * 2007-08-28 2013-07-30 Baxter International Inc. Method for producing viral vaccines
CA2797059A1 (en) * 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
PL2855513T3 (pl) 2012-06-01 2017-05-31 Boehringer Ingelheim Vetmedica Gmbh Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie
JP6257607B2 (ja) 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド 癌免疫療法のための組成物および方法
MX361680B (es) 2012-12-13 2018-12-13 Aduro Biotech Inc Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP5865942B2 (ja) 2014-04-16 2016-02-17 三菱電機株式会社 内燃機関のシリンダ吸入空気量推定装置および推定方法
CA2979215A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3714039B1 (en) 2017-11-22 2025-03-12 HDL Therapeutics, Inc. Methods for priming fluid circuits of a plasma processing system
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN111629751B (zh) 2018-01-22 2025-02-21 美国政府(由卫生和人类服务部的部长所代表) 广泛保护性灭活流感病毒疫苗
US11643641B2 (en) * 2021-03-04 2023-05-09 Malireddy S. Reddy Prevention of viral transmission by naked genetic material

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
DE2321951C2 (de) * 1973-05-02 1975-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer Diphtherie-Vaccine
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
GB1503388A (en) * 1975-07-01 1978-03-08 Inverni Della Beffa Spa Pharmaceutically active complexes and pharmaceutical compositions containing them
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) * 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
EP0250128A3 (en) * 1986-06-18 1988-06-08 American Registry of Pathology Novel virus isolated from patients with aids
DE3707987A1 (de) * 1987-03-12 1988-09-22 Behringwerke Ag Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole
GB8906794D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Preparation of vaccines

Also Published As

Publication number Publication date
DE69227400D1 (de) 1998-12-03
EP0514199A2 (en) 1992-11-19
AU652447B2 (en) 1994-08-25
SG49763A1 (en) 1998-06-15
EP0514199A3 (en) 1993-11-10
ZA923607B (en) 1993-02-24
ATE172642T1 (de) 1998-11-15
US5698432A (en) 1997-12-16
ES2127203T3 (es) 1999-04-16
KR0149182B1 (ko) 1998-10-15
NZ242780A (en) 1994-07-26
BR9201848A (pt) 1993-01-05
JPH05328967A (ja) 1993-12-14
AU1634092A (en) 1992-12-17
CA2068817A1 (en) 1992-11-18
EP0514199B1 (en) 1998-10-28
IE921556A1 (en) 1992-11-18
GB9110808D0 (en) 1991-07-10
KR920021162A (ko) 1992-12-18
IN174080B (enExample) 1994-09-10

Similar Documents

Publication Publication Date Title
DE69227400T2 (de) Impfstoffe und Verfahren zu ihrer Herstellung
EP0864646B1 (de) Verfahren zur Inaktivierung von lipidumhüllten Viren
KR0162646B1 (ko) 보조제로서 토콜을 함유한 백신 및 그것의 제조방법
DE69225710T3 (de) Anregung von antworten zytotoxischer t-lymphozyten
DE69831594T2 (de) Intakte oder zerstörte insektenzellen als antigenadjuvant
DE60118228T2 (de) Mikropartikel zur verabreichung von heterologen nukleinsäure
DE69635871T2 (de) Verfahren und Zusammensetzungen zur selektiven Modikation von Nukleinsäuren
DE69333814T2 (de) Genetischer impfstoff gegen den immunschwäche virus
DE69814177T2 (de) Impfstoffe mit einem ltb adjuvans
DE69427824T2 (de) Impfstoffe bestehend aus protein- oder peptid-"cochleaten" und deren verwendung zur immunisierung
PL212212B1 (pl) Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
DE69936337T2 (de) Verfahren zur entwicklung von einem hiv impfstoff
DE69910253T2 (de) Verfahren zur herstellung von inaktivierten, w/ö emulsion adjuvierten, impfstoffen
EP0222974B1 (de) Verfahren zur Herstellung eines Tollwutimpfstoffes und nach diesem Verfahren erhaltener Impfstoff
DE69514217T2 (de) Rekombinante plasmide enthaltende zusammensetzung und ihre verwendung als impstoff und arzneimittel
WO1993014197A1 (en) Hypericin treatment of vaccine agents for improved immunogenicity
DE69633919T2 (de) Mehrzweckvakzine gegen umhüllte viren
US4057626A (en) Process for detoxifying influenza B virus
CA2529965C (en) Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
DE3854857T2 (de) Verhütung und behandlung einer retrovirenkrankheit
DE69116155T2 (de) Neuramidase und glulaktoseoxidase als vaccinadjuvans
DE3005495C2 (de) Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen
DE2528584A1 (de) Verfahren zur inaktivierung der virusinfektiositaet unter gleichzeitiger stabilisierung von virusantigenen
DE69938168T2 (de) Erysipelothrix rhusiopathiae Antigene und Impfstoff-Zusammensetzungen
US20080317780A1 (en) Viral vaccine and method for preparation thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ISTITUTO SIEROVACCINOGENO ITALIANO I.S.I. S.P.A.,

8339 Ceased/non-payment of the annual fee